Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PASG
- Price
- 12.70
- Stock movement up
- +0.38 (3.08%)
- Company name
- Passage Bio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 40.37M
- Ent value
- 30.64M
- Price/Sales
- 12.57
- Price/Book
- 1.30
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -73.10%
- 1 year return (CAGR)
- -99.74%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PASG does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 12.57 |
| Price to Book | 1.30 |
| EV to Sales | 9.54 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.18M |
| EPS (TTM) | -14.28 |
| FCF per share (TTM) | -10.57 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.21M |
| Gross profit (TTM) | -1.12M |
| Operating income (TTM) | -49.72M |
| Net income (TTM) | -45.26M |
| EPS (TTM) | -14.28 |
| EPS (1y forward) | -6.38 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -34.87% |
| Operating margin (TTM) | -1547.88% |
| Profit margin (TTM) | -1409.22% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 52.77M |
| Net receivables | 0.00 |
| Total current assets | 55.73M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 21.90M |
| Total assets | 74.16M |
| Accounts payable | 952.00K |
| Short/Current long term debt | 24.34M |
| Total current liabilities | 22.25M |
| Total liabilities | 43.04M |
| Shareholder's equity | 31.12M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -33.47M |
| Capital expenditures (TTM) | 14.00K |
| Free cash flow (TTM) | -33.49M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -145.45% |
| Return on Assets | -61.04% |
| Return on Invested Capital | -130.59% |
| Cash Return on Invested Capital | -96.61% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.82 |
| Daily high | 14.10 |
| Daily low | 12.62 |
| Daily Volume | 71K |
| All-time high | 288560.00 |
| 1y analyst estimate | 39.60 |
| Beta | 1.86 |
| EPS (TTM) | -14.28 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PASG | S&P500 | |
| Current price drop from All-time high | -100.00% | -0.89% |
| Highest price drop | -100.00% | -19.00% |
| Date of highest drop | 7 Nov 2025 | 8 Apr 2025 |
| Avg drop from high | -99.21% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
40.37M
Marketcap category
Small-cap
Description
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Employees
60
Website
Investor relations
-
SEC filings
CEO
Bruce A. Goldsmith
Country
USA
City
Philadelphia
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page